Presentation of Phase 1b study in PMM patients at Mitochondrial Diseases Conference (Rome, Italy).Announced plans to study REN001 in PMM patients with nDNA defects.Food and Drug Administration and European Medicines Agency that positive data from the STRIDE and STRIDE AHEAD studies could potentially support registration of REN001 for PMM patients with mtDNA defects Enrolled over 80% of the population in the ongoing pivotal STRIDE study.Finally, we are now in the process of planning both a Phase 2 study in LC-FAOD patients and a study in PMM patients with nDNA defects,” concluded Mr. Furthermore, we announced positive results from the Phase 1b study in long-chain fatty acid oxidation disorders (LC-FAOD) patients with nuclear DNA (nDNA) defects. Moreover, we are pleased that the majority of patients who completed STRIDE are electing to enroll into the long-term STRIDE AHEAD safety study. We remain on track to announce topline data from this study in the fourth quarter of 2023. “As of today, we have achieved over 80% enrollment in the ongoing pivotal STRIDE study in primary mitochondrial myopathy (PMM) patients with mitochondrial DNA (mtDNA) defects. Flesher, President and CEO of Reneo Pharmaceuticals. “We continued to advance our REN001 development programs during the third quarter,” said Gregory J. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended September 30, 2022. 08, 2022 (GLOBE NEWSWIRE) - Reneo Pharmaceuticals, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |